Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
about
Midostaurin: an emerging treatment for acute myeloid leukemia patientsMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyInvestigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaPhase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Rational Combinations of Targeted Agents in AMLEvolving treatment strategies in patients with high-risk acute myeloid leukemia.Novel therapeutics in acute myeloid leukemia.Natural product and natural product derived drugs in clinical trials.Targeting FLT3 to treat leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Midostaurin for the treatment of acute myeloid leukemia.Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.Hypomethylating Agents as a Therapy for AML.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Midostaurin: First Global Approval.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.Precision therapy for acute myeloid leukemia.Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease
P2860
Q26749271-2910F4B8-8237-4A4B-8B78-D972775B4CDBQ26749870-E91153D0-3E4E-4113-99EB-11CD2E71685FQ33943277-14137013-8AA0-4BD6-99E9-9ACC36FDFBE3Q35224437-01069C1E-3E5A-4CF4-A8A4-E7293FE6C1E2Q35750491-AB14F3B1-7078-4D8A-B2F2-A5FE2FDEB6A5Q38179026-518E24E2-85C1-4FAD-A7BC-DDB25D1AF2AAQ38196346-216596AD-EC73-43C0-BF3D-F1E170B23307Q38247457-6ECE91AC-EAF2-454B-A45A-3676352BFB66Q38251339-024044ED-77DE-4CD0-A2EF-2EE1EC810B4CQ38664735-D5775676-7D63-44CA-8C70-5C3081A04CD8Q38671401-45208347-DC84-4743-B967-BE260DE8C58EQ38864977-1C4B11D1-D347-4F01-BDB1-D237B70C9E79Q38911864-240302F4-0C47-468A-BE55-E069CE852C9BQ38913785-5018723A-F512-4B60-9366-FFBBA287D527Q39045977-5F5D5921-7547-4195-A9CA-B5A3A9DF896DQ39175665-3E2FC8F5-DC12-4907-8F42-ADFD420A3D1FQ39371391-90B9278B-7398-4A40-8169-8151ABFBFEE0Q42376734-C890F763-BFA5-4A3A-A2BA-23A457F676DEQ46210383-C6122583-607B-46B3-82FB-A8396A4B3036Q47727992-D20D6CA3-D573-4983-832A-FBF107358210Q47877035-437D8B7C-ADB8-4027-AEC0-302607545B3EQ49376791-EB8CA25F-A33D-4C06-AD79-F89023003F1AQ49534332-7CF59E7F-7768-4685-88B0-25A330772000Q49614743-25D004F4-A239-4615-96DA-0AF6486CC33AQ58699279-5DD44507-20E3-41D3-B0C8-704D9CC71EE4
P2860
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Preclinical and phase I result ...... s with acute myeloid leukemia.
@en
Preclinical and phase I results of decitabine in combination with midostaurin
@nl
type
label
Preclinical and phase I result ...... s with acute myeloid leukemia.
@en
Preclinical and phase I results of decitabine in combination with midostaurin
@nl
prefLabel
Preclinical and phase I result ...... s with acute myeloid leukemia.
@en
Preclinical and phase I results of decitabine in combination with midostaurin
@nl
P2093
P2860
P356
P1433
P1476
Preclinical and phase I result ...... s with acute myeloid leukemia.
@en
P2093
Allan Fleming
Casey B Williams
Catherine Dutreix
Joseph P McGuirk
Kapil N Bhalla
Omar Aljitawi
Ruben Reyes
Siddartha Ganguly
Suman Kambhampati
P2860
P304
P356
10.1002/PHAR.1316
P407
P577
2013-06-24T00:00:00Z